Zhongguo Fei Ai Za Zhi · Sep 20, 2026

Research Advances in Exhaled Breath Condensate Multi-omics for the Diagnosis and Clinical Translation of Non-small Cell Lung Cancer

By Hu Q, Liu P, Zhu R et al.

Non-small cell lung cancer (NSCLC) is the predominant histological subtype of lung cancer and it is characterized by high incidence, insidious onset, and poor prognosis. Early diagnosis remains challenging, as low-dose spiral computed tomography (LDCT) screening has a high false-positive rate, highlighting the need for more specific adjunctive diagnostic approaches. As a lung-proximal, non-invasive liquid biopsy, exhaled breath condensate (EBC) can directly reflect alterations in the local airway microenvironment and is increasingly emerging as an important complement to conventional liquid biopsy approaches. In recent years, EBC research has evolved from single-omics biomarker screening toward integrated multi-omics analyses encompassing genomics, transcriptomics, proteomics, and metabolomics. Meanwhile, the introduction of technologies such as microfluidics, nanosensing, and artificial intelligence algorithms has helped overcome key challenges associated with the high dilution of EBC samples and the trace abundance of target molecules. This review systematically summarizes recent advances in EBC research, including the standardization of sample collection, multi-omics biomarker discovery, innovations in detection technologies, and clinical translation. Particular emphasis is placed on the clinical value of EBC in the early screening, molecular subtyping, therapeutic response monitoring, and early warning of drug resistance in NSCLC. Current challenges and future directions are also discussed, with the aim of providing a reference for advancing EBC-based multi-omics technologies toward precision diagnosis and treatment in clinical practice. .

doi.org/10.3779/j.issn.1009-3419.2026.101.25PubMed 43051934Biomarkers

AgingResearch.News